Page last updated: 2024-11-05

methanesulfonyl fluoride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methanesulfonyl fluoride: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11207
CHEMBL ID4297433
MeSH IDM0046448

Synonyms (28)

Synonym
4-04-00-00027 (beilstein handbook reference)
unii-9h250yyy0r
9h250yyy0r ,
EN300-35716
methanesulfonyl fluoride
fumette
mesyl fluoride
fluoro methyl sulfone
methanesulphonyl fluoride
hsdb 6397
einecs 209-192-2
brn 1740836
MSF ,
methanesulfonyl fluoride, 98%
558-25-8
A830828
AKOS005207314
FT-0628291
snx-001
methane sulfonyl fluoride
methylsufonyl fluoride
ch3so2f
DTXSID8060329
DB13058
Q6823571
methanesulfonyl-fluoride
CHEMBL4297433
Z361886230

Research Excerpts

Overview

Methanesulfonyl fluoride (MSF) is a CNS-selective acetylcholinesterase (AChE) inhibitor. Currently being developed and tested for the treatment of symptoms of Alzheimer's disease.

ExcerptReferenceRelevance
"Methanesulfonyl fluoride (MSF) is a CNS-selective acetylcholinesterase (AChE) inhibitor, currently being developed and tested for the treatment of symptoms of Alzheimer's disease. "( Prenatal exposure to the acetylcholinesterase inhibitor methanesulfonyl fluoride alters forebrain morphology and gene expression.
Byers, DM; Hohmann, CF; Irwin, LN; Moss, DE; Sumaya, IC, 2005
)
2.02

Toxicity

ExcerptReferenceRelevance
" No patients left the study because of drug-related adverse events and there were no toxic effects."( Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type.
Berlanga, P; Hagan, MM; Ishida, C; Moss, DE; Sandoval, H, 1999
)
1.75

Dosage Studied

ExcerptRelevanceReference
" MSF produced a dose-response function of %inhibition = (40)(Log10[MSF mg/kg] + 51."( Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type.
Berlanga, P; Hagan, MM; Ishida, C; Moss, DE; Sandoval, H, 1999
)
1.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (60.00)18.7374
1990's4 (16.00)18.2507
2000's4 (16.00)29.6817
2010's2 (8.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.79 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index46.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.45%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (93.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers [NCT01269476]Phase 127 participants (Actual)Interventional2009-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]